Simonyi Gábor
Pest Megyei Flór Ferenc Kórház, Kardiometabolikus Centrum V. Belgyógyászat-Lipidológiai Osztály, Regionális Zsíranyagcsere-központ és Hypertonia Decentrum, Kistarcsa.
Orv Hetil. 2012 May 6;153(18):695-701. doi: 10.1556/OH.2012.29351.
Sodium-glucose co-transporters (SGLTs) have a key role in the re-absorption of glucose in the kidneys. Therefore, inhibition of SGLTs may provide a novel therapeutic strategy for diabetes mellitus. SGLT2 inhibitors enhance renal glucose excretion by inhibiting renal glucose re-absorption and reduce plasma glucose level, as well as they decrease the body weight. Their action is insulin independent and they improve insulin resistance in diabetes mellitus. Numerous SGLT2 inhibitors have been developed and evaluated in clinical trials. Phase III trials are needed to assess the safety of SGLT2 inhibitors. Results suggest that the beneficial effects of SGLT2 inhibition might be achieved without the development of significant side effects.
钠-葡萄糖协同转运蛋白（SGLTs）在肾脏对葡萄糖的重吸收中起关键作用。因此，抑制SGLTs可能为糖尿病提供一种新的治疗策略。SGLT2抑制剂通过抑制肾脏对葡萄糖的重吸收来增加肾脏葡萄糖排泄，降低血糖水平，同时还能减轻体重。它们的作用不依赖胰岛素，并且能改善糖尿病患者的胰岛素抵抗。许多SGLT2抑制剂已被研发并在临床试验中进行评估。需要进行III期试验来评估SGLT2抑制剂的安全性。结果表明，抑制SGLT2可能在不产生明显副作用的情况下实现有益效果。
